Relapsed / Refractory · Phase III randomized; N=314; EGFR-mutated, MET-amplified advanced NSCLC after EGFR-TKI resistance. Dalmelitinib + aumolertinib vs platinum chemotherapy. Primary endpoint BICR PFS. · Median PFS 6.2 vs 4.4 months

Dalmelitinib plus aumolertinib

Primary setting: Relapsed / Refractory · Disease extent: Advanced / metastatic · Prior-treatment context: Relapsed / refractory or previously treated population; see trial-specific eligibility

Clinical question: Does dual MET/EGFR inhibition improve PFS over platinum chemotherapy in EGFR-mutated, MET-amplified NSCLC after EGFR-TKI resistance?

Median PFS 6.2 vs 4.4 months; HR 0.60 (95% CI 0.45–0.81; P<0.001). ORR 59.6% vs 38.6%; DoR 9.7 vs 4.4 months; OS immature. · Registry:

Design, population and treatment

Phase III randomized; N=314; EGFR-mutated, MET-amplified advanced NSCLC after EGFR-TKI resistance. Dalmelitinib + aumolertinib vs platinum chemotherapy. Primary endpoint BICR PFS.

Key efficacy outcome

6.2 · intervention

4.4

6.2 · comparator

Not calculable from median PFS.

Grade ≥3 TEAEs 50.0% vs 51.0%; hepatic lab abnormalities more frequent with targeted regimen; haematologic toxicity with chemotherapy.

Safety and absolute effect

Median PFS (months)

https://pubmed.ncbi.nlm.nih.gov/42928710/

Interpretation and limitations

Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.

Primary source

Primary publication · DOI: 10.1200/JCO-26-02432